Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results.
Cerenome has launched its CNSide CSF Molecular Profile tests in the U.S. This expansion allows for the ordering of these diagnostics from Oct. 12, 2026, extending their application beyond leptomeningeal metastases to include primary central nervous system (CNS) tumors, CNS metastases, and hematologic CNS disease.
CNSide Diagnostics, a subsidiary of Cerenome, announced the commercial launch of its CNSide® CSF Molecular Profile Tests. These new DNA and RNA tests expand the company's CNSide offering beyond leptomeningeal metastases to encompass molecular profiling across CNS oncology.